Image of William Huynh

William Huynh

Antitrust & Foreign Investment Counsel, New York

Overview

Education and qualifications

Published works

Overview

Will advises on U.S. merger control in international M&A transactions. Will also counsels clients on cartel and other antitrust conduct. Prior to joining Linklaters, Will was an attorney at the U.S. Federal Trade Commission, where he investigated mergers in a variety of industries, including pharmaceutical manufacturing and distribution, medical devices, and technology.

Representative experience
  • Novartis: advising on various matters, including:
    • its US$3.5bn acquisition of Chinook Therapeutics.
    • its US$1.1bn acquisition of Kate Therapeutics.
    • its US$925m acquisition of Anthos Therapeutics.
    • its collaboration and license agreement with BeiGene.
    • its acquisition of Spinifex Pharmaceuticals.
  • Novo Holdings: advising on its US$16.5bn acquisition of Catalent.
  • Linde: advising on its US$70bn global business combination with Praxair.
  • Perfetti van Melle: advising on its US$1.35bn acquisition of Mondelez’s developed-market gum business in the United States, Canada and Europe.
  • Novozymes: advising on its US$12.3bn merger with Chr. Hansen Holding.
  • Bayer: advising on the US$7.6bn divestiture of its animal health business to Elanco Animal Health.
  • Dr. Reddy’s Laboratories Ltd.: advising on its US$350m acquisition of Teva/Allergan divestiture products.

Education and qualifications

Will received his Juris Doctorate in 2011 from University of Virginia School of Law. Prior to that, in 2005, he obtained his Bachelor of Arts from Cornell University.

Published works

Co-author (with Douglas Tween), “Antitrust: How to navigate a perilous but underappreciated compliance risk area”, Concurrences Nº 1-2020, Feb 2020